Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Cash & Equivalents (2016 - 2025)

Wave Life Sciences (WVE) has disclosed Cash & Equivalents for 11 consecutive years, with $602.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Equivalents rose 99.32% year-over-year to $602.1 million, compared with a TTM value of $602.1 million through Dec 2025, up 99.32%, and an annual FY2025 reading of $602.1 million, up 99.32% over the prior year.
  • Cash & Equivalents was $602.1 million for Q4 2025 at Wave Life Sciences, up from $196.2 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $602.1 million in Q4 2025 and bottomed at $88.5 million in Q4 2022.
  • Average Cash & Equivalents over 5 years is $197.8 million, with a median of $163.5 million recorded in 2023.
  • The sharpest move saw Cash & Equivalents tumbled 42.74% in 2021, then skyrocketed 126.39% in 2023.
  • Year by year, Cash & Equivalents stood at $150.6 million in 2021, then tumbled by 41.22% to $88.5 million in 2022, then skyrocketed by 126.39% to $200.4 million in 2023, then surged by 50.77% to $302.1 million in 2024, then skyrocketed by 99.32% to $602.1 million in 2025.
  • Business Quant data shows Cash & Equivalents for WVE at $602.1 million in Q4 2025, $196.2 million in Q3 2025, and $208.5 million in Q2 2025.